The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...

However, some research suggests that poor sleep could raise your risk of Alzheimer’s. A study published in November found ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Dr Eric Berg DC has shared 'hidden dangers' and numerous health risks of the problem that affects many at night ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

According to the Alzheimer’s Association ( there are currently 6.5 million people with Alzheimer’s disease. An estimated 6.9 ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...

Taking longer to drift into the dreaming phase – known as rapid eye movement (REM) sleep – could be an early sign of Alzheimer's disease, potentially opening up new ways to diagnose and treat the ...

Clinical trials have demonstrated that the drug can delay deterioration by four to six months, targeting the beta-amyloid protein in the brain. Another medication, donanemab, has received approval but ...